President, NGM Biopharmaceuticals
Jeff is the President of NGM Bio, where he has led this research-driven biotechnology company committed to discovering and developing novel biologics for the treatment of life-threatening diseases since 2014. During his years at the company, he helped craft the broad collaboration with Merck, expand the pipeline to six clinical candidates, more than double the team and substantially expand the cash balance. Prior to joining NGM, Jeff was the Senior Vice President, Corporate and Business Development at Theravance Biopharma (NASDAQ: TBPH) and held that same role at Theravance, Inc. (NASDAQ: THRX) before completing the spin out of TBPH. He previously served as the Chief Business Officer of Satori Pharmaceuticals, Vice President of Business Development and Corporate Strategy for Gloucester Pharmaceuticals prior to its acquisition by Celgene (NASDAQ: CELG) and a Global Head of Business Development at Genentech amongst other roles in the business development and legal groups there. Jeff began his career as an attorney in the Technology Transactions Group at Wilson, Sonsini, Goodrich & Rosati, representing clients in the life science and high-tech industries. Jeff holds a J.D. from Columbia University School of Law, an M.LITT. from the University of St. Andrews, Scotland and a B.A. from Claremont McKenna College.